Concord Biotech Q1 Results FY27: What to Expect

Concord Biotech Q1 Results FY27 prediction is based on Screener.in consolidated quarterly financials for the Q1 FY26 base quarter, with the Uniresearch trailing-growth model applied to project the Q1 FY27 estimate. Concord Biotech reported Revenue of Rs 204 Cr and PAT of Rs 44 Cr in Q1 FY26, forming the base for the Concord Biotech Q1 Results FY27 forecast of Rs 193 Cr Revenue and Rs 32 Cr PAT. Prepared by Kunal Singla, Associate Director.

Click Here – Get Free Investment Predictions

Concord Biotech Q1 Results FY27: Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change
Revenue (Rs Cr)	204	193	-5.6%
PAT (Rs Cr)	44	32	-26.7%

Source: Q1 FY26 actuals from Screener.in consolidated quarterly financial data. Q1 FY27 prediction for Concord Biotech applies Uniresearch trailing growth rates (Revenue -5.6%, PAT -26.7%) to Q1 FY26 verified actuals.

Track Concord Biotech Live on Univest Screener

Q4 FY26 Performance: Base for the Prediction

The Concord Biotech Q1 Results FY27 prediction is anchored on Q4 FY26 consolidated Revenue of Rs 326 Cr and PAT of Rs 88 Cr per quarterly financial data. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 FY27 Uniresearch projection.

The sequential comparison also provides useful context. Q4 FY26 Revenue of Rs 326 Cr reflects year-end execution cycles that may not repeat equally in Q1 FY27. The more meaningful benchmark is the year-on-year comparison against Q1 FY26 Revenue of Rs 204 Cr, where the Uniresearch estimate targets -5.6% growth. Both reads should be monitored when the actual Q1 FY27 numbers are declared.

Uniresearch Estimate Behind the Concord Biotech Q1 Results FY27 Projection

The Concord Biotech Q1 Results FY27 prediction is derived from Uniresearch trailing analysis, which estimates Q1 FY27 Revenue growth of -5.6% and PAT growth of -26.7% year-on-year. Uniresearch applies these trailing growth rates to Q1 FY26 actuals to arrive at the Q1 FY27 projection of Rs 193 Cr Revenue and Rs 32 Cr PAT.

The Q1 FY27 estimation methodology for Concord Biotech is worth clarifying for investors. Uniresearch applies full-year FY27 trailing growth rates (-5.6% Revenue, -26.7% PAT) uniformly to Q1 FY26 verified actuals to derive the quarterly projection. This approach assumes the quarterly trajectory broadly mirrors the full-year trend direction. Intra-year seasonality and one-time events can cause divergence. Treat this Q1 FY27 Uniresearch estimate for Concord Biotech as a directional benchmark, not a point forecast.

Get Expert Stock Picks on Univest

Key Watchpoints for the Concord Biotech Q1 Results FY27

Revenue vs Estimate

Whether Concord Biotech Q1 Results FY27 Revenue delivers in line with the Rs 193 Cr Uniresearch estimate (-5.6% YoY). Q4 FY26 Revenue was Rs 326 Cr.

PAT Margin Sustainability

PAT of Rs 32 Cr (-26.7% YoY) is the Concord Biotech Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 88 Cr. Margin stability signals operating leverage.

Management Commentary and Full-Year FY27 Guidance

Beyond Q1 FY27 headline numbers, Concord Biotech’s management commentary will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation. A confident outlook post an in-line result could support re-rating.

Risks to the Concord Biotech Q1 Results FY27 Prediction

Below-Estimate Revenue Growth

If actual Q1 FY27 Revenue underperforms the -5.6% growth target, the Rs 193 Cr prediction would be revised downward.

PAT Pressure from Costs or Provisions

One-time charges, higher input costs, or elevated provisions could push PAT below Rs 32 Cr.

External and Macro Environment

The Q1 FY27 performance is also exposed to macro-level risks including global commodity price movements, rupee-dollar volatility, domestic interest rate changes, and FII/DII sentiment shifts. A deteriorating macro environment in Q1 FY27 could create downside risk even if company-specific execution remains on track.

Concord Biotech Q1 Results FY27: Sector Growth Drivers

Sector positioning in the pharmaceuticals and life sciences sector. The following tailwinds and headwinds will shape the result.

Domestic Formulation Growth

India’s domestic pharma market grows at 8-10% annually, led by chronic therapies and branded generics.

Regulated Market Export Pipeline

USFDA-approved facilities and a growing ANDA pipeline offer incremental export revenues.

Use Univest Screener to Track Concord Biotech Live

Concord Biotech Q1 Results FY27: Conclusion

The Concord Biotech Q1 Results FY27 Uniresearch projection of Revenue Rs 193 Cr and PAT Rs 32 Cr is derived from trailing growth rates applied to Q1 FY26 actuals. Track Concord Biotech live on the Univest Screener for real-time updates.

Once the actual Q1 FY27 result for Concord Biotech is declared, compare it directly against the Uniresearch estimate to assess beat, meet, or miss. Use Univest research and screener tools to stay updated post the result announcement and to track any revision to the full-year FY27 outlook.

Download the Univest iOS App or Univest Android App for live Q1 FY27 result alerts.

Frequently Asked Questions on Concord Biotech Q1 Results FY27

What is the Uniresearch prediction for Concord Biotech Q1 Results FY27?

Ans. Uniresearch projects Q1 FY27 Revenue for Concord Biotech at Rs 193 Cr (-5.6% YoY) and PAT at Rs 32 Cr (-26.7% YoY), based on trailing analysis of Q1 FY26 actuals. Q1 FY26 Revenue was Rs 204 Cr and PAT Rs 44 Cr. Treat as directional estimate.

What growth rate assumptions are used in the Uniresearch estimate for Concord Biotech Q1 Results FY27?

Ans. The Uniresearch estimate applies trailing YoY growth rates (Revenue -5.6%, PAT -26.7%) derived from historical quarterly data to Q1 FY26 actuals (Revenue Rs 204 Cr, PAT Rs 44 Cr). These are directional estimates, not guarantees.

What were the Q4 FY26 actuals behind the Concord Biotech Q1 Results FY27 projection?

Ans. Q4 FY26 consolidated Revenue was Rs 326 Cr and PAT was Rs 88 Cr. These Q4 FY26 actuals serve as the most recent sequential reference alongside the Q1 FY26 base.

How reliable is the Concord Biotech Q1 Results FY27 Uniresearch prediction?

Ans. The Q1 Results FY27 estimate is a Uniresearch trailing projection, not a guaranteed outcome. Actual results may differ due to macro conditions, seasonal variation, and company-specific execution. Use the projection as a directional benchmark and compare against declared actuals on the Univest Screener.

What base data is used for the Concord Biotech Q1 Results FY27 Uniresearch projection?

Ans. The Q1 FY27 projection for Concord Biotech uses Q1 FY26 consolidated actuals (Revenue Rs 204 Cr, PAT Rs 44 Cr) from Screener.in quarterly data. Trailing growth rates (-5.6% Revenue, -26.7% PAT) are applied to derive the Q1 FY27 estimate.

What are the key risks to the Concord Biotech Q1 Results FY27 estimate?

Ans. Key risks to the Q1 Results FY27 estimate for Concord Biotech include usfda regulatory risk, us generic pricing erosion, and broader macro headwinds. Any of these could cause actual Q1 FY27 Revenue or PAT to undershoot the Uniresearch projection.

When will Concord Biotech declare the actual Concord Biotech Q1 Results FY27 data?

Ans. Concord Biotech will declare Q1 FY27 results after Q1 FY27 ends, typically shortly after Q1 FY27 ends. The board meeting date will be disclosed via NSE or BSE filings. Track live updates on the Univest Screener.